Gainers

• Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market session. The company's market cap stands at $66.4 million.
• ProMIS Neurosciences (NASDAQ:PMN) shares increased by 13.39% to $13.29. The company's market cap stands at $109.4 million.
• OPKO Health (NASDAQ:OPK) shares increased by 12.9% to $1.4. The company's market cap stands at $921.2 million. As per the press release, Q2 earnings came out today.
• OrthoPediatrics (NASDAQ:KIDS) shares moved upwards by 12.08% to $22.22. The market value of their outstanding shares is at $484.6 million.
• Matinas BioPharma Hldgs (AMEX:MTNB) stock increased by 11.35% to $0.37. The market value of their outstanding shares is at $1.5 million.
• Olema Pharmaceuticals (NASDAQ:OLMA) stock increased by 9.57% to $13.16. The company's market cap stands at $1.0 billion.

Losers

• Radiopharm Theranostics (NASDAQ:RADX) stock declined by 12.6% to $3.2 during Monday's after-market session. The market value of their outstanding shares is at $27.6 million.
• Redhill Biopharma (NASDAQ:RDHL) stock decreased by 8.59% to $0.64. The company's market cap stands at $3.8 million.
• HeartSciences (NASDAQ:HSCS) shares declined by 7.91% to $2.33. The company's market cap stands at $7.8 million. As per the press release, Q4 earnings came out 2 days ago.
• iBio (NASDAQ:IBIO) shares decreased by 7.58% to $1.34. The market value of their outstanding shares is at $71.0 million.
• Cumberland Pharma (NASDAQ:CPIX) stock decreased by 6.77% to $6.55. The market value of their outstanding shares is at $99.0 million.
• Scinai Immunotherapeutics (NASDAQ:SCNI) shares decreased by 6.61% to $0.23. The company's market cap stands at $1.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.